Laboratório de Química do Estado Sólido
 LQES NEWS  portfólio  em pauta | pontos de vista | vivência lqes | lqes cultural | lqes responde 
 o laboratório | projetos e pesquisa | bibliotecas lqes | publicações e teses | serviços técno-científicos | alunos e alumni 

LQES
lqes news
novidades de C&T&I e do LQES

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

LQES News anteriores

em foco

hot temas

 
NOVIDADES

Nanomedicine stops superbugs in their tracks.

A team of researchers led by the University of South Australia has discovered a way to find and beat superbugs, providing a critical breakthrough against many deadly infectious diseases.

Researchers from the ARC Centre of Excellence in Bio-Nano Science and Technology (CBNS), including the University of South Australia, have developed a nanomedicine capable of carrying antibiotics into hard-to-reach infected cells (Antibiotics"Rifampicin-Loaded Mesoporous Silica Nanoparticles for the Treatment of Intracellular Infections ").

Professor Clive Prestidge, from UniSA's School of Pharmacy and Medical Sciences and the Cancer Research Institute, says the technology shows promise in successfully treating golden staph infections which kill around 700,000 people globally each year, including 260 Australians.

The team, including UniSA PhD student Santhni Subramaniam, has successfully used microscopic nano particles to carry an anti-tuberculosis drug into the cells of infected micro worms to kill hidden bacteria.

They expect the method to work just as well on urinary tract infections, bone and wound infections.

“Over time, bacteria have learnt how to hide in human cells, making some diseases resistant to antibiotics. To get around this challenge we have put the antibiotic into a very, very small vehicle that enables it to go into the body and kill the invading bacteria hiding in the cells,” Prof Prestidge says.

The nanoscale capsules containing the antibiotics are literally eaten by the infected cells, which then die at a much higher rate, Subramaniam explains.

While human trials are a few years off, the researchers hope that because they are using approved antibiotics in a more effective and targeted way, this treatment could be saving lives within eight years.

“The time to take it from concept to human clinical trials to market is significantly reduced when we compare it with a new drug mode,” Prof Prestidge says.

“There are a number of technologies that are being developed to counter these superbugs. This is just one, but hopefully for humankind we are going to have a number of these coming into play over the coming years.”

University of South Australia. Posted: Aug 20, 2019.



<< voltar para novidades

 © 2001-2020 LQES - lqes@iqm.unicamp.br sobre o lqes | políticas | link o lqes | divulgação | fale conosco